Sugi Predict

Sugi Predict / Compounds / Cysteine

Cysteine

Cysteine

SCHEMBL987552

N[C@@H](CS)C(=O)O.O=C1C=CC(=O)N1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 2/20 0.61
▸ SLC7A11 Q9UPY5 1/20 0.61
▸ GSK3A P49840 1/20 0.42
▸ GSK3B P49841 1/20 0.42
▸ CCR6 P51684 1/20 0.42
▸ SLC7A5 Q01650 2/20 0.37
▸ ALPI P09923 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ XIAP P98170 1/20 0.37
▸ GRIK1 P39086 2/20 0.37
▸ GRIA1 P42261 2/20 0.37
▸ GRIA2 P42262 2/20 0.37
▸ GRIA3 P42263 2/20 0.37
▸ GRIA4 P48058 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ENPEP Q07075 2/20 0.36
▸ IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cysteine SCHEMBL16208953 1.00 PTGS1 (0.61) PTGS1SLC7A11GSK3AGSK3BCCR6
Cysteine SCHEMBL27864571 1.00 PTGS1 (0.61) PTGS1SLC7A11GSK3AGSK3BCCR6
Aspartic Acid SCHEMBL29564328 0.81 GSK3A (0.42) PTGS1GSK3AGSK3BCCR6SLC7A5
Aspartic Acid SCHEMBL29024585 0.81 GSK3A (0.42) PTGS1GSK3AGSK3BCCR6SLC7A5
Cystine SCHEMBL28236509 0.79 GSK3A (0.41) GSK3AGSK3BCCR6
Cysteine SCHEMBL28009382 0.79 PTGS1 (0.89) PTGS1SLC7A11SLC7A5ALPIPKM
Cysteine SCHEMBL95110 0.78 — —
Cysteine SCHEMBL339562 0.78 PTGS1 (1.00) PTGS1SLC7A11SLC7A5GRIK1GRIA1
Cysteine SCHEMBL7898895 0.78 PTGS1 (1.00) PTGS1SLC7A11SLC7A5GRIK1GRIA1
Cysteine SCHEMBL4289403 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077049-A1 COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF ELICIO THERAPEUTICS INC (US) 2026-03-19 — — US claimed
US-20250249107-A1 COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF ELICIO THERAPEUTICS INC (US) 2025-08-07 — — US claimed
US-20250009888-A1 COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF ELICIO THERAPEUTICS INC (US) 2025-01-09 — — US claimed
US-12138301-B2 Compounds including a mutant KRAS sequence and a lipid and uses thereof Elicio Therapeutics, Inc. (US) 2024-11-12 — — US claimed
CN-118421594-A Compounds comprising mutant KRAS sequences and lipids and uses thereof 伊莱西奥治疗有限公司 2024-08-02 — — CN claimed
CN-112118847-B Compounds comprising mutant KRAS sequences and lipids and uses thereof 伊莱西奥治疗有限公司 2024-05-28 — — CN claimed
EP-4319822-A2 ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF Minerva Biotechnologies Corporation (US) 2024-02-14 — — EP claimed
CN-114133428-B Amphotericin B hydrophilic polypeptide derivative and application thereof 华东理工大学 2023-10-27 — — CN claimed
WO-2023201234-A2 ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF MINERVA BIOTECHNOLOGIES CORPORATION (US) 2023-10-19 — — WO claimed
CN-109073647-B Droplet interior surface engineering for capture of molecular targets 斯特拉斯堡大学 2022-07-12 — — CN claimed
US-20190343963-A1 CONJUGATED PROTEASE TARGETING MOIETIES MEDIMMUNE LIMITED (GB) 2019-11-14 — — US claimed
EP-3545076-A1 NUCLEIC ACID SEQUENCING DEVICE CONTAINING GRAPHENE Roswell Biotechnologies, Inc (US) 2019-10-02 — — EP claimed
US-20190113509-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-04-18 — — US claimed
EP-3440463-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET Université de Strasbourg (FR) 2019-02-13 — — EP claimed
WO-2018098286-A1 NUCLEIC ACID SEQUENCING DEVICE CONTAINING GRAPHENE Roswell Biotechnologies, Inc. (US) 2018-05-31 — — WO claimed
WO-2017182651-A1 CONJUGATED PROTEASE TARGETING MOIETIES MEDIMMUNE LIMITED (GB) 2017-10-26 — — WO claimed
WO-2017174610-A1 INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET UNIVERSITE DE STRASBOURG (FR) 2017-10-12 — — WO claimed
EP-2571897-B1 NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE BETTA PHARMACEUTICALS CO LTD (CN) 2014-11-05 — — EP claimed
EP-0840619-A1 PREVENTION AND TREATMENT OF SEPSIS OPHIDIAN PHARMACEUTICALS, INC. (US) 1998-05-13 — — EP claimed
WO-1996040251-A1 PREVENTION AND TREATMENT OF SEPSIS OPHIDIAN PHARMACEUTICALS, INC. (US) 1996-12-19 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009888-A1 COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF KRAS, NRAS, HRAS PTGS1 4399/4885SLC7A11 2029/4885GSK3A 4172/4885
US-20250249107-A1 COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF KRAS, NRAS, HRAS PTGS1 4399/4885SLC7A11 2029/4885GSK3A 4172/4885
US-20260077049-A1 COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOF KRAS, NRAS, CDC42 PTGS1 4270/4885SLC7A11 1595/4885GSK3A 2244/4885
US-12138301-B2 Compounds including a mutant KRAS sequence and a lipid and uses thereof KRAS, NRAS, PIK3CA PTGS1 1805/4885SLC7A11 1282/4885GSK3A 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.